The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2020 | PEMREC: neo-adjuvant pembrolizumab and RT in rectal cancer
Thibaud Kössler, MD, PhD, of Geneva University Hospital, Geneva, Switzerland, discusses the rationale and trial design of PEMREC (NCT04109755), an ongoing Phase II study evaluating safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy (RT) in localized microsatellite stable rectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
